| Purpose | BGI SENTIS Leukemia Gene Detection (DNA): Leukemia Gene Panel (DNA) enables for identification of mutations including SNV, InDels and CNVs in 183 leukemia related genes associated with hematological malignancies. It is suitable for following major myeloid and lymphoid disorders: - Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
SUITABLE FOR: Gene List (183 Genes associated with hematological malignancies |
| Test Code | BGI SENTIS Leukemia Gene Detection (DNA) |
| Turnaround Time (TAT) | 20 Days |
| Sample Tested | BGI SENTIS Leukemia Gene Detection (DNA)- Peripheral blood ≥5mL OR Saliva ≥ 2mL OR ≥ 2-3mL Bone Marrow
|
| Methodology | - DNA Extraction and QC.
- Targeted Capture of 183 leukemia related genes associated with hematological malignancies.
- Highly sensitive detection of actionable mutations from Blood or Bone Marrow samples in 183 leukemia related genes associated with hematological malignancies.
- Reports having information for targeted drugs (Precision Medicine).
- Genetic Counselling.
|
| Advantages | BGI SENTIS Leukemia Gene Detection (DNA)- All exons plus flanking intronic regions covered for all genes tested (183 leukemia related genes associated with hematological malignancies); one single assay that detects all above mentioned gene mutations in coding region, 1000+ fusion types and four types of variations for following major myeloid and lymphoid disorders:
- A streamlined sample-to-results workflow with MGI’s platform and automated on-premises NGS bioinformatics system, enabling effortless obtainment of insightful reports from samples.
- Providing molecular evidence for the consideration of targeted therapies (Precision Medicine).
|
